We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Europe Allows Sale of Genetically Modified Corn

By Biotechdaily staff writers
Posted on 25 May 2004
Despite reservations on the part of many of the member states, the European Commission has announced it will allow the sale of Bt-11 sweet corn, thereby ending a six-year moratorium on the import of genetically modified (GM) food products. More...
The ruling will allow the import of Bt-11 corn already canned and ready for the supermarket shelf. Members of the European Union (EU) will not be allowed to cultivate Bt-11 sweet corn.

Bt-11 sweet corn was developed by Syngenta (Basel, Switzerland). Normal maize (Zea mays) was modified by the insertion of a gene from the bacterium Bacillus thuringiensis that produces the Bt protein Cry1Ab. When eaten by the European corn borer or corn earworm, two important sweet corn pests, digestive enzymes in the alkaline environment of the larva's intestine metabolize Cry1Ab, yielding a shorter protein that binds to the wall of the intestine. Following binding, pores are formed that disrupt midgut ion flow, causing gut paralysis and eventual death from bacterial sepsis. Cry1Ab is lethal only when eaten by the larvae of lepidopteran insects (moths and butterflies), and its specificity of action is directly attributable to the presence of specific binding sites in the target insects. There are no binding sites for the delta-endotoxins of B thuringiensis on the surface of mammalian intestinal cells. Therefore, livestock animals and humans are not susceptible to these proteins.

The safety of Bt-11 sweet corn for use as a food has been demonstrated by digestibility studies, toxicity studies, and allergenicity studies. The composition and nutritional value of Bt-11 has been shown to be comparable or substantially equivalent to non-Bt sweet corn. Objection to the use of GM corn is based primarily on anecdotal reports such as those of livestock dying of "mysterious” illnesses after having been fed genetically modified maize. Other concerns center on the genetic stability of the modified plants and on the activity of the Bt genes as they move up the food chain.

While the World Health Organization (WHO, Geneva, Switzerland) is strongly promoting GM foods as the key to preventing food shortages in the coming decades, the success of GM foods in Europe will largely be determined by the willingness of consumers to buy them.




Related Links:
Syngenta

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Autoimmune Hepatitis Test
LKM-1-Ab ELISA
New
Drug Test Kit
DrugCheck 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.